CHICAGO -- The novel intranasal agent etripamil was safe and rapidly converted most patients with paroxysmal supraventricular tachycardia (PSVT) back into normal rhythm, the phase II NODE-1 trial ...

CHICAGO, IL — A nasal spray containing the calcium-channel blocker etripamil could allow patients to convert acute paroxysmal supraventricular tachycardia (PSVT) outside the hospital, phase 2 data ...

Up to 2 million people in the U.S. experience rapid-fire heartbeats from time to time, and many end up in the hospital for treatment. But an investigational nasal spray may help folks with paroxysmal ...

It is the end of the day, and you have finished your last case in the electrophysiology laboratory. On your way to speak with the patient's family, an eager young house officer stops you in the ...

MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Cardamyst (etripamil) is a nose spray that helps treat sudden episodes of fast heartbeats, known as paroxysmal supraventricular tachycardia (PSVT). PSVT is a type of abnormal heart rhythm where your ...

Many health care providers are dissatisfied with the lack of effective treatment options with people with PSVT, often requiring prolonged, burdensome, and costly trips to the emergency department or ...

A clinical trial led by Weill Cornell Medicine investigators showed that a nasal spray that patients administer at home, without a physician, successfully and safely treated recurrent episodes of a ...

CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT ...

CARDAMYST is now conveniently available to patients through retail pharmacies National sales force hired with promotional launch in mid-February Expected $25 copay cap for eligible commercially ...